Results 71 to 80 of about 35,110 (216)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. [PDF]

, 2015
BackgroundThis retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by evaluating the impact of prior activity and intervening time interval.MethodsEighty ...
Eng, C, Falchook, GS, Fu, S, Garrett, C, George, GC, Hess, K, Hong, DS, Janku, F, Karp, D, Kopetz, S, Kurzrock, R, Liu, X, Meric-Bernstam, F, Naing, A, Overman, MJ, Piha-Paul, SA, Raghav, K, Subbiah, V, Tsimberidou, AM, Wheler, JJ, Zinner, R   +20 more
core   +2 more sources

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab

BMC Cancer, 2023
Background Radioimmunotherapy with cetuximab and conjugates with various radioisotopes is a feasible treatment option for different tumor models. Scandium-47 (47Sc), one of several β−-particle-emitting radioisotopes, displays favorable physical and ...
Da-Mi Kim, So-Young Lee, Jae-Cheong Lim, Eun-Ha Cho, Ul-Jae Park   +4 more
doaj   +1 more source

PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab

Frontiers in Cell and Developmental Biology, 2021
BackgroundCetuximab is an effective antibody to treat colorectal cancer (CRC) by targeting the epidermal growth factor receptor (EGFR). However, the mechanisms of acquired resistance to cetuximab therapy, especially in patients without identifiable gene ...
Qizhi Liu, Cheng Xin, Yikuan Chen, Yikuan Chen, Jiawen Yang, Yingying Chen, Wei Zhang, Lechi Ye   +7 more
doaj   +1 more source

Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation. [PDF]

, 2015
Photochemical internalisation (PCI) is a technique for improving cellular delivery of certain bioactive agents which are prone to sequestration within endolysosomes.
Adigbli, Adigbli, Arentsen, Baglo, Berg, Berg, Berg, Berg, Berstad, Bodles-Brakhop, Bostad, Bostad, Bull-Hansen, Castano, Castano, Chong, Dietze, Dietze, Elisabeth Olsen, Fretz, Gaware, Gooding, Gottesman, Hirschberg, Høgset, Jørgensen, Kunz, Lai, Lai, Lakshmanan, Lou, Lu, Lund, Mathews, Mroz, Mroz, Norum, Norum, Norum, Norum, Pasparakis, Peng, Peng, Prasmickaite, Reginato, Rosenblum, Selbo, Selbo, Selbo, Selbo, Selbo, Selbo, Selbo, Selbo, Selbo, St Denis, Stratford, Todorova, Vikdal, Wang, Wang, Wang, Weyergang, Weyergang, Woodhams, Xu, Yaghini, Yao, Yip, Zahreddine   +69 more
core   +1 more source

EPMA position paper in cancer:current overview and future perspectives [PDF]

, 2015
At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM). Individual patients will participate in more aspects of their healthcare.
Bubnov, Rostylav, Danesi, Romano, Desiderio, Dominic M., Grech, Godfrey, Hagan, Suzanne, Vittadini, Giorgio, Yoo, Byong Chul, Zhan, Xianquan   +7 more
core   +5 more sources

Resistance to Cetuximab in EGFR-Overexpressing Esophageal Squamous Cell Carcinoma Xenografts Due to FGFR2 Amplification and Overexpression

Journal of Pharmacological Sciences, 2014
Esophageal carcinoma is one of the most virulent malignant diseases and a major cause of cancer-related deaths worldwide. Despite improvements in surgical techniques and perioperative management and surgery combined with chemotherapy and/or radiotherapy,
Yi Zhang, Tiecheng Pan, Xiaoxuan Zhong, Cai Cheng   +3 more
doaj   +1 more source

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

BMC Cancer, 2020
Background KRAS mutations have been characterized as the major predictive biomarkers for resistance to cetuximab treatment. However, studies indicate that not all KRAS mutations are associated with equivalent treatment outcomes.
Hangyu Zhang, Liyun Yuan, Lulu Liu, Cong Yan, Jinming Cheng, Qihan Fu, Zhou Tong, Weiqin Jiang, Yi Zheng, Peng Zhao, Guoqing Zhang, Weijia Fang   +11 more
doaj   +1 more source

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study

BMC Cancer, 2022
Background Patients with BRAF V600E mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The introduction of BRAF targeted therapy with encorafenib and weekly administered cetuximab have shown improved survival with a median progression ...
Martina Eriksen, Per Pfeiffer, Kristoffer Staal Rohrberg, Christina Westmose Yde, Lone Nørgård Petersen, Laurids Østergaard Poulsen, Camilla Qvortrup   +6 more
doaj   +1 more source

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. [PDF]

, 2016
Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing radiation (IR).
Adams, Stephen R, Advani, Sunil J, Aguilera, Joe, Cohen, Ezra EW, Crisp, Jessica L, Jones, Karra A, Lippman, Scott M, Savariar, Elamprakash N, Tsien, Roger Y, Whitney, Michael A, Yang, Howard C   +10 more
core   +1 more source

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. [PDF]

, 2010
Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aberrant signaling downstream of this receptor contributes to tumor growth.
Bigner, DD, Chiosea, SI, Gooding, WE, Grandis, JR, Kuan, C-T, Lai, SY, Leeman-Neill, RJ, Sen, M, Suzuki, S, Thomas, SM, Wheeler, SE   +10 more
core